Somatic mutation in Primary Sjögren's Syndrome

原发性干燥综合征的体细胞突变

基本信息

  • 批准号:
    MR/P002005/1
  • 负责人:
  • 金额:
    $ 76.94万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2016
  • 资助国家:
    英国
  • 起止时间:
    2016 至 无数据
  • 项目状态:
    已结题

项目摘要

Autoimmune diseases affect 5% of the population and cause a wide range of painful disabilities that affect quality of life and may lead to life-threatening complications and early death. The most common autoimmune diseases in order of prevalence are rheumatoid arthritis, primary Sjögren's syndrome (PSS) and SLE or 'lupus'. In all these conditions, the immune system becomes hyperactive and damages tissues of the body including the joints, skin, mucous membranes, glands and vital organs. In health, immune responses are closely regulated so that auto-immunity dose not occur. Although research has identified many new ways to suppress auto-immunity, the 'aetiology' or fundamental reason that the immune system escapes control, is completely unknown.Through this research we are testing a new hypothesis that could explain why immune responses escape control in autoimmune disease. Throughout life, tissues of the body accumulate genetic mutations due to random errors in copying the DNA when cells divide. These mutations are known as 'somatic' mutations to indicate that they occur within an individual's lifetime and are not inherited from one generation to the next. Somatic mutations are the cause of cancer and may play an important role in many chronic and age-related diseases. Our research aims to test whether somatic mutations also cause autoimmunity. The idea is that genes that control immune responses may become defective so that immune cells escape from normal regulatory signals. There is evidence to support this idea from rare patients who are born with mutations that develop autoimmunity at a young age. We also know that patients with autoimmunity, especially those with PSS, are at risk of developing lymphoma and that some patients with lymphoma-related diseases get autoimmune problems. Our hypothesis suggests that somatic mutation is the factor linking both autoimmunity and lymphomaThe evidence we are looking for is whether patients with PSS have somatic DNA mutations in the immune cells that are causing their disease. Patients with PSS suffer dryness and severe irritation because their tear glands, salivary glands and other glands are attacked by immune cells. They are invited to join a UK Register and to allow their tissue biopsies to be used for research. We will use the latest tissue dissection methods to purify small populations of immune cells from the salivary glands of PSS patients and then ultra-sensitive DNA sequencing to detect somatic mutations in the DNA of the cells. If we find mutations, we will then determine which particular cell or cells of the immune system have the mutations and what problems the mutations cause in order to understand exactly how a mutation leads to the disease.This research promises to change our understanding of autoimmunity. If the hypothesis is correct then we anticipate that DNA mutation testing will become a new way to diagnose autoimmune disease, to predict how serious the condition will be and to monitor treatment. It will also provide specific information that will enable drugs to be targeted to individual somatic mutations. Ultimately this will improve the treatment of patients with autoimmune disease, enhancing their health and economic welfare and reducing the burden of autoimmune disease upon society.
自身免疫性疾病影响5%的人口,并导致各种痛苦的残疾,影响生活质量,并可能导致危及生命的并发症和过早死亡。最常见的自身免疫性疾病按患病率顺序为类风湿性关节炎、原发性干燥综合征(PSS)和SLE或“狼疮”。在所有这些情况下,免疫系统变得过度活跃并损害身体组织,包括关节,皮肤,粘膜,腺体和重要器官。在健康的情况下,免疫反应受到密切调节,因此不会发生自身免疫。尽管研究已经发现了许多抑制自身免疫的新方法,但免疫系统逃脱控制的“病因”或根本原因是完全未知的。通过这项研究,我们正在测试一个新的假设,可以解释为什么免疫反应在自身免疫性疾病中逃脱控制。在整个生命过程中,由于细胞分裂时复制DNA的随机错误,身体组织会积累基因突变。这些突变被称为“体细胞”突变,表明它们发生在个体的一生中,而不是从一代遗传到下一代。体细胞突变是癌症的原因,并可能在许多慢性和年龄相关疾病中发挥重要作用。我们的研究旨在测试体细胞突变是否也会导致自身免疫。这个想法是,控制免疫反应的基因可能会变得有缺陷,从而使免疫细胞逃避正常的调节信号。有证据支持这一观点,来自罕见的患者,他们出生时就有突变,在年轻时就会产生自身免疫。我们还知道,自身免疫患者,尤其是PSS患者,有患淋巴瘤的风险,并且一些患有淋巴瘤相关疾病的患者会出现自身免疫问题。我们的假设表明,体细胞突变是连接自身免疫和淋巴瘤的因素。我们正在寻找的证据是,PSS患者的免疫细胞中是否存在导致其疾病的体细胞DNA突变。PSS患者遭受干燥和严重刺激,因为他们的泪腺,唾液腺和其他腺体受到免疫细胞的攻击。他们被邀请加入英国注册,并允许他们的组织活检用于研究。我们将使用最新的组织解剖方法从PSS患者的唾液腺中纯化小群免疫细胞,然后进行超灵敏的DNA测序来检测细胞DNA中的体细胞突变。如果我们发现了突变,我们将确定免疫系统的哪个或哪些特定细胞有突变,以及突变会导致什么问题,以便准确了解突变是如何导致疾病的。这项研究有望改变我们对自身免疫的理解。如果这一假设是正确的,那么我们预计DNA突变检测将成为诊断自身免疫性疾病、预测病情严重程度和监测治疗的新方法。它还将提供特定的信息,使药物能够针对个体体细胞突变。最终,这将改善自身免疫性疾病患者的治疗,提高他们的健康和经济福利,减少自身免疫性疾病对社会的负担。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
  • DOI:
    10.1038/s41467-021-26551-x
  • 发表时间:
    2021-10-29
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Lin WY;Fordham SE;Hungate E;Sunter NJ;Elstob C;Xu Y;Park C;Quante A;Strauch K;Gieger C;Skol A;Rahman T;Sucheston-Campbell L;Wang J;Hahn T;Clay-Gilmour AI;Jones GL;Marr HJ;Jackson GH;Menne T;Collin M;Ivey A;Hills RK;Burnett AK;Russell NH;Fitzgibbon J;Larson RA;Le Beau MM;Stock W;Heidenreich O;Alharbi A;Allsup DJ;Houlston RS;Norden J;Dickinson AM;Douglas E;Lendrem C;Daly AK;Palm L;Piechocki K;Jeffries S;Bornhäuser M;Röllig C;Altmann H;Ruhnke L;Kunadt D;Wagenführ L;Cordell HJ;Darlay R;Andersen MK;Fontana MC;Martinelli G;Marconi G;Sanz MA;Cervera J;Gómez-Seguí I;Cluzeau T;Moreilhon C;Raynaud S;Sill H;Voso MT;Lo-Coco F;Dombret H;Cheok M;Preudhomme C;Gale RE;Linch D;Gaal-Wesinger J;Masszi A;Nowak D;Hofmann WK;Gilkes A;Porkka K;Milosevic Feenstra JD;Kralovics R;Grimwade D;Meggendorfer M;Haferlach T;Krizsán S;Bödör C;Stölzel F;Onel K;Allan JM
  • 通讯作者:
    Allan JM
GATA2 deficiency phenotype associated with tandem duplication of GATA2 and overexpression of GATA2-AS1.
  • DOI:
    10.1182/bloodadvances.2021005217
  • 发表时间:
    2021-12-28
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    Singh P;Heer M;Resteu A;Mikulasova A;Reza M;Largeaud L;Dufrechou S;Prade N;Dickinson RE;Bustamante J;Neven B;Bigley V;Delabesse E;Rico D;Pasquet M;Collin M
  • 通讯作者:
    Collin M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew Collin其他文献

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party
造血干细胞移植后达雷木单抗治疗纯红细胞再生障碍性贫血:欧洲骨髓移植学会移植并发症工作组的研究与实践考虑
  • DOI:
    10.1038/s41408-025-01315-8
  • 发表时间:
    2025-06-04
  • 期刊:
  • 影响因子:
    11.600
  • 作者:
    Nico Gagelmann;Moniek de Witte;Christophe Peczynski;William Boreland;Annoek E. C. Broers;Edgar Jost;Alexander Kulagin;Albert Esquirol;Simona Sica;Jürgen Kuball;Gerardo Errico;Wolfgang Bethge;Johan Maertens;Friedrich Stölzel;Edouard Forcade;Matthew Collin;Matteo Parma;Goda Choi;Nicolaus Kröger;Maria Chiara Di Chio;Maria Chiara Finazzi;Lucia López Corral;Jose Rifón;Alberto Mussetti;Adrian Bloor;Marco Ladetto;Hélène Schoemans;Olaf Penack;Ivan Moiseev;Zinaida Peric
  • 通讯作者:
    Zinaida Peric
The impact of beneficial ownership transparency on illicit purchases of U.S. property
受益所有权透明度对非法购买美国财产的影响
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Matthew Collin;Florian M. Hollenbach;David Szakonyi
  • 通讯作者:
    David Szakonyi
In AML Patients Allografted in First Remission, emDNMT3A/em Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
在首次缓解时进行同种异体移植的急性髓系白血病患者中,根据核型、NPM1 和 FLT3-ITD 突变状态,emDNMT3A/em 突变对移植后结果有差异影响 - 来自欧洲血液和骨髓移植学会急性白血病工作组
  • DOI:
    10.1182/blood-2024-202764
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Iman Abou Dalle;Jacques-Emmanuel Galimard;Xavier Poiré;Jaime Sanz;Anne Huynh;Nicolaus Kröger;Eva-Maria Wagner Drouet;David Burns;Matthias Eder;Bruno Lioure;Depei Wu;Jiri Mayer;Kristina Carlson;Matthias Stelljes;Matthew Collin;Mahmoud Aljurf;Arnon Nagler;Jordi Esteve;Fabio Ciceri;Ali Bazarbachi;Mohamad Mohty
  • 通讯作者:
    Mohamad Mohty
Human dendritic cell deficiency: the missing ID?
人类树突状细胞缺陷:缺失的识别码?
  • DOI:
    10.1038/nri3046
  • 发表时间:
    2011-08-19
  • 期刊:
  • 影响因子:
    60.900
  • 作者:
    Matthew Collin;Venetia Bigley;Muzlifah Haniffa;Sophie Hambleton
  • 通讯作者:
    Sophie Hambleton
Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
同种异体造血细胞移植受者诺卡氏菌感染的危险因素:欧洲血液和骨髓移植学会传染病工作组的病例对照研究。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    28.2
  • 作者:
    J. de Greef;D. Averbuch;L. Tondeur;A. Duréault;T. Zuckerman;Xavier Roussel;Christine Robin;A. Xhaard;Simona Pagliuca;Yves Beguin;C. Botella;Nina Khanna;A. L. Bourgeois;J. V. Praet;A. Ho;Nicolaus Kröger;S. Leprêtre;D. Roos;M. Aljurf;Nicole Blijlevens;I. Blau;K. Carlson;Matthew Collin;A. Ganser;A. Villate;Johannes Lakner;S. Martin;A. Nagler;Ron Ram;Anna Torrent;Maria Stamouli;Malgorzata Mikulska;Lidia Gil;L. Wendel;Gloria Tridello;N. Knelange;R. de la Cámara;Olivier Lortholary;Arnaud Fontanet;J. Styczyński;Johan Maertens;J. Coussement;D. Lebeaux
  • 通讯作者:
    D. Lebeaux

Matthew Collin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew Collin', 18)}}的其他基金

HistioNode: The MRC Rare Disease Platform Node for Histiocytic Disorders
HistioNode:用于组织细胞疾病的 MRC 罕见疾病平台节点
  • 批准号:
    MR/Y008189/1
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
    Research Grant
The role of clonal haematopoiesis in immune-mediated inflammatory diseases
克隆造血在免疫介导的炎症性疾病中的作用
  • 批准号:
    MR/T004231/1
  • 财政年份:
    2019
  • 资助金额:
    $ 76.94万
  • 项目类别:
    Research Grant

相似国自然基金

配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
  • 批准号:
    82371616
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
Pik3r2基因突变在家族内侧颞叶癫痫中的作用及发病机制研究
  • 批准号:
    82371454
  • 批准年份:
    2023
  • 资助金额:
    47.00 万元
  • 项目类别:
    面上项目
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
  • 批准号:
    82371652
  • 批准年份:
    2023
  • 资助金额:
    45.00 万元
  • 项目类别:
    面上项目
22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
  • 批准号:
    82370906
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
RET基因634位点不同氨基酸改变对甲状腺C细胞的影响与机制研究
  • 批准号:
    82370790
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
KMT2A基因突变通过DNMT3靶向调控GBP2导致神经发育障碍的机制研究
  • 批准号:
    82371867
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
Consequences of MALT1 mutation for B cell tolerance
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
错义突变介导的TGR5持续活化与功能丧失在胆管纤维化与结石形成中的作用及机制研究
  • 批准号:
    81960125
  • 批准年份:
    2019
  • 资助金额:
    30.0 万元
  • 项目类别:
    地区科学基金项目
Vici综合征致病基因Epg5自噬缺陷的高通量筛选
  • 批准号:
    31900533
  • 批准年份:
    2019
  • 资助金额:
    26.0 万元
  • 项目类别:
    青年科学基金项目
Dravet综合征基因突变分析及突变来源研究
  • 批准号:
    81171221
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目

相似海外基金

Sodium channel mutations as a possible cause for primary dysautonomia
钠通道突变可能是原发性自主神经功能障碍的原因
  • 批准号:
    10586393
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
The essential roles of primary cilia in heterotopic ossification
初级纤毛在异位骨化中的重要作用
  • 批准号:
    10734116
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
Primary hepatocyte and engineered iPSC-derived hepatocyte-like cell transplantation to treat alpha-1 antitrypsin deficiencyassociated liver disease
原代肝细胞和工程 iPSC 衍生的肝细胞样细胞移植治疗 α-1 抗胰蛋白酶缺乏相关的肝病
  • 批准号:
    10607039
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation Resistance
采用新型头颈癌原发小鼠模型来克服放化疗耐药性
  • 批准号:
    10918580
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
The Role of Monoallelic Expression in Incomplete Penetrance of Primary Immunodeficiencies
单等位基因表达在原发性免疫缺陷不完全外显中的作用
  • 批准号:
    10752095
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
Fluid biomarkers in primary tauopathies
原发性 tau 蛋白病中的液体生物标志物
  • 批准号:
    10648906
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
Mechanisms that Enhance and Suppress HIV-1 Resistance in Gene Edited Primary Human Cells
增强和抑制基因编辑原代人类细胞中 HIV-1 耐药性的机制
  • 批准号:
    10700726
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
Role of a latent OriLyt RNA in KSHV latency in primary effusion lymphoma
潜伏 OriLyt RNA 在原发性渗出性淋巴瘤 KSHV 潜伏期中的作用
  • 批准号:
    10761865
  • 财政年份:
    2023
  • 资助金额:
    $ 76.94万
  • 项目类别:
Metabolomic Analysis of Primary Human Meningioma and Schwannoma following Radiation Therapy: A Novel Approach to Identify Targetable Radiosensitive Pathways
放射治疗后原发性人类脑膜瘤和神经鞘瘤的代谢组学分析:识别靶向放射敏感途径的新方法
  • 批准号:
    10536483
  • 财政年份:
    2022
  • 资助金额:
    $ 76.94万
  • 项目类别:
The primary role of low NCOA6 expression in the prostate cancer disparity among African American men
NCOA6 低表达在非裔美国男性前列腺癌差异中的主要作用
  • 批准号:
    10544740
  • 财政年份:
    2022
  • 资助金额:
    $ 76.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了